Aptorum Group Collaborates with DiamiR on Alzheimer's Biomarkers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 22 2026
0mins
Aptorum Group and DiamiR Biosciences announced a collaboration between DiamiR and AlzLabs Precision Diagnostics to generate protein and microRNA blood-based biomarker data with the focus on Alzheimer's disease.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APM
About APM
Aptorum Group Limited is a United Kingdom-based clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The Company's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Andean Precious Metals Reports Record Revenue and EBITDA for 2025
- Record Revenue: Andean Precious Metals Corp achieved $134 million in revenue for 2025, reflecting a significant growth that enhances investor confidence and positions the company favorably in the precious metals market.
- Strong Adjusted EBITDA: The company reported an adjusted EBITDA of $47 million in Q4 and $133 million for the full year 2025, indicating improved operational efficiency and profitability, which may attract increased institutional investor interest.
- Cash Flow and Liquid Assets: With liquid assets of $167 million at year-end 2025 and free cash flow of $36 million in Q4, the company is well-positioned for future expansion and investments, bolstering its competitive stance in the market.
- Production and Cost Challenges: Although gold equivalent production finished near the low end of guidance, cash costs at Golden Queen reached $1,698 per ounce, highlighting potential impacts from global supply chain volatility and high oil prices on operational costs, necessitating close attention to future cost management strategies.
See More
Aptorum Group Receives Nasdaq Compliance Notification
- Compliance Notification: Aptorum Group received a notification from Nasdaq on March 5, indicating that it is not in compliance with the minimum bid price requirement of $1 per share, although this notice does not immediately affect its listing or trading on Nasdaq.
- Grace Period Granted: The company has been granted a 180-calendar-day grace period until September 1, 2026, to regain compliance, providing time to evaluate potential solutions to ensure its stock continues trading on Nasdaq.
- Potential Actions: Aptorum stated it will consider options to restore compliance during the grace period, including a potential reverse stock split if necessary, which could impact shareholder equity and market confidence.
- Market Response: Despite facing compliance challenges, Aptorum must actively communicate its recovery plans to maintain investor confidence and prevent further declines in stock price.
See More
Aptorum Group Receives Nasdaq Non-Compliance Notification
- Non-Compliance Notification: Aptorum Group received a notification from Nasdaq on March 5, 2026, regarding non-compliance with the minimum bid price of $1 per share, indicating potential challenges that may affect investor confidence.
- Grace Period Granted: The company has been granted a 180-calendar-day grace period until September 1, 2026, to regain compliance, providing a window to implement necessary measures to avoid delisting risks.
- Compliance Restoration Plans: During this grace period, Aptorum intends to evaluate all available options, including a potential reverse stock split, demonstrating its commitment to maintaining its Nasdaq listing.
- Company Overview: Aptorum Group focuses on the discovery and development of therapeutic assets for unmet medical needs, and despite compliance challenges, its core business retains potential market value.
See More
Andean Precious Metals Corp. Raises C$83.1M by Selling 7.9M Shares at C$10.50 Each
- Share Issuance Plan: Andean Precious Metals Corp. has entered into an agreement with PMB Partners to sell 7.9 million common shares at C$10.50 each, raising a total of C$83.1 million, aimed at enhancing interest from institutional investors and improving liquidity.
- Shareholder Ownership Changes: Following the offering, founder Alberto Morales's ownership will decrease from 53.22% to 47.94%, yet he will remain the largest shareholder, demonstrating a continued commitment to the company's long-term strategy.
- Market Access Strategy: The offering will be publicly issued in all Canadian provinces via a prospectus supplement and may be offered to qualified institutional buyers in the U.S., indicating the company's proactive strategy in expanding market reach and attracting new investors.
- Liquidity Enhancement Commitment: Andean Precious Metals has committed not to issue new shares for 90 days post-offering to avoid shareholder dilution, thereby enhancing market trading liquidity and boosting investor confidence.
See More
Andean Precious Metals Corp. Completes C$83.1 Million Secondary Offering
- Offering Overview: Andean Precious Metals Corp. has entered into an agreement with PMB Partners to sell 7.915 million common shares at C$10.50 each, generating gross proceeds of C$83.1 million, aimed at enhancing institutional investor interest and improving liquidity.
- Shareholder Ownership Changes: Following the offering, founder Alberto Morales's ownership will decrease from 53.22% to 47.94%, yet he will remain the largest shareholder, reflecting his ongoing commitment to the company's strategic vision.
- Liquidity Enhancement: This secondary offering allows Andean to avoid shareholder dilution while increasing the public float, which is expected to improve trading liquidity and attract new investors.
- Future Outlook: The offering is anticipated to close on January 28, 2026, subject to necessary corporate and regulatory approvals, further supporting the company's long-term growth strategy and market expansion plans.
See More
Aptorum Group to Enhance Board and Management Team with Experienced Executives Amid DiamiR Biosciences Merger Plans
New Board Appointment: Aptorum Group Limited has appointed Dr. Laura A. Philips as an independent director following its merger with DiamiR Biosciences Corp, bringing extensive experience in life sciences and technology development.
Merger Details: The all-stock merger between Aptorum and DiamiR is expected to close in the fourth quarter of 2025, subject to shareholder approval, with key personnel from DiamiR joining the combined company's board and executive team.
See More
Andean Precious Metals Reports Record Revenue and EBITDA for 2025
- Record Revenue: Andean Precious Metals Corp achieved $134 million in revenue for 2025, reflecting a significant growth that enhances investor confidence and positions the company favorably in the precious metals market.
- Strong Adjusted EBITDA: The company reported an adjusted EBITDA of $47 million in Q4 and $133 million for the full year 2025, indicating improved operational efficiency and profitability, which may attract increased institutional investor interest.
- Cash Flow and Liquid Assets: With liquid assets of $167 million at year-end 2025 and free cash flow of $36 million in Q4, the company is well-positioned for future expansion and investments, bolstering its competitive stance in the market.
- Production and Cost Challenges: Although gold equivalent production finished near the low end of guidance, cash costs at Golden Queen reached $1,698 per ounce, highlighting potential impacts from global supply chain volatility and high oil prices on operational costs, necessitating close attention to future cost management strategies.
See More
Aptorum Group Receives Nasdaq Compliance Notification
- Compliance Notification: Aptorum Group received a notification from Nasdaq on March 5, indicating that it is not in compliance with the minimum bid price requirement of $1 per share, although this notice does not immediately affect its listing or trading on Nasdaq.
- Grace Period Granted: The company has been granted a 180-calendar-day grace period until September 1, 2026, to regain compliance, providing time to evaluate potential solutions to ensure its stock continues trading on Nasdaq.
- Potential Actions: Aptorum stated it will consider options to restore compliance during the grace period, including a potential reverse stock split if necessary, which could impact shareholder equity and market confidence.
- Market Response: Despite facing compliance challenges, Aptorum must actively communicate its recovery plans to maintain investor confidence and prevent further declines in stock price.
See More
Aptorum Group Receives Nasdaq Non-Compliance Notification
- Non-Compliance Notification: Aptorum Group received a notification from Nasdaq on March 5, 2026, regarding non-compliance with the minimum bid price of $1 per share, indicating potential challenges that may affect investor confidence.
- Grace Period Granted: The company has been granted a 180-calendar-day grace period until September 1, 2026, to regain compliance, providing a window to implement necessary measures to avoid delisting risks.
- Compliance Restoration Plans: During this grace period, Aptorum intends to evaluate all available options, including a potential reverse stock split, demonstrating its commitment to maintaining its Nasdaq listing.
- Company Overview: Aptorum Group focuses on the discovery and development of therapeutic assets for unmet medical needs, and despite compliance challenges, its core business retains potential market value.
See More
Andean Precious Metals Corp. Raises C$83.1M by Selling 7.9M Shares at C$10.50 Each
- Share Issuance Plan: Andean Precious Metals Corp. has entered into an agreement with PMB Partners to sell 7.9 million common shares at C$10.50 each, raising a total of C$83.1 million, aimed at enhancing interest from institutional investors and improving liquidity.
- Shareholder Ownership Changes: Following the offering, founder Alberto Morales's ownership will decrease from 53.22% to 47.94%, yet he will remain the largest shareholder, demonstrating a continued commitment to the company's long-term strategy.
- Market Access Strategy: The offering will be publicly issued in all Canadian provinces via a prospectus supplement and may be offered to qualified institutional buyers in the U.S., indicating the company's proactive strategy in expanding market reach and attracting new investors.
- Liquidity Enhancement Commitment: Andean Precious Metals has committed not to issue new shares for 90 days post-offering to avoid shareholder dilution, thereby enhancing market trading liquidity and boosting investor confidence.
See More
Andean Precious Metals Corp. Completes C$83.1 Million Secondary Offering
- Offering Overview: Andean Precious Metals Corp. has entered into an agreement with PMB Partners to sell 7.915 million common shares at C$10.50 each, generating gross proceeds of C$83.1 million, aimed at enhancing institutional investor interest and improving liquidity.
- Shareholder Ownership Changes: Following the offering, founder Alberto Morales's ownership will decrease from 53.22% to 47.94%, yet he will remain the largest shareholder, reflecting his ongoing commitment to the company's strategic vision.
- Liquidity Enhancement: This secondary offering allows Andean to avoid shareholder dilution while increasing the public float, which is expected to improve trading liquidity and attract new investors.
- Future Outlook: The offering is anticipated to close on January 28, 2026, subject to necessary corporate and regulatory approvals, further supporting the company's long-term growth strategy and market expansion plans.
See More
Aptorum Group to Enhance Board and Management Team with Experienced Executives Amid DiamiR Biosciences Merger Plans
New Board Appointment: Aptorum Group Limited has appointed Dr. Laura A. Philips as an independent director following its merger with DiamiR Biosciences Corp, bringing extensive experience in life sciences and technology development.
Merger Details: The all-stock merger between Aptorum and DiamiR is expected to close in the fourth quarter of 2025, subject to shareholder approval, with key personnel from DiamiR joining the combined company's board and executive team.
See More
